Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Calithera Biosciences (Nasdaq: CALA) announced that CEO Susan Molineaux will present at the H.C. Wainwright VIRTUAL BioConnect Conference on January 11, 2021. The presentation will be accessible via webcast for 30 days on their investor relations website. Calithera focuses on developing novel small molecule drugs targeting cancer and other serious diseases, emphasizing improving treatment options for patients. The company is committed to advancing its pipeline of therapies, although future clinical outcomes and approvals carry inherent risks and uncertainties.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on January 11, 2021, and a webcast for replay for up to 30 days at www.calithera.com in the Investor Relations section.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Incorporated
CONTACTS:
Investor Relations
Jennifer McNealey
Calithera
ir@Calithera.com
650-870-1071
Media
Michele Parisi
Sam Brown, Inc.
micheleparisi@sambrown.com
925-864-5028
FAQ
When will Calithera Biosciences present at the H.C. Wainwright BioConnect Conference?
What is the focus of Calithera Biosciences?
How can I access the presentation by Calithera's CEO?
What are the risks mentioned in Calithera's press release?
Where is Calithera Biosciences headquartered?
